نتایج جستجو برای: 266
تعداد نتایج: 5967 فیلتر نتایج به سال:
Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 5.9 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216 6.3 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 7.7 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 7.7 20 to 24 years . . . . . . . . . . . . . . . . . . . . ....
رامسر یکی از شهرهای ساحلی شمال ایران دارای مناطق با پرتوزایی طبییعی بالا است
3 Minimum cost network flow problem 5 3.1 Transportation problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3.2 The maximum flow problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.3 The shortest path problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.4 The single source shortest paths . . . . . . . . . . . . . . . . ...
A new Synechocystis 6714 mutant, IoxIIA, resistant to the phenol-type herbicide ioxynil was isolated and characterized. The mutation found in the psbA gene (encoding the D 1 photosystem II protein) is at the same codon 266 as for the first ioxynil-resistant mutant IoxIA previously selected [G. Ajlani, I. Meyer, C. Vernotte, and C. Astier, FEBS Lett. 246, 207-210 (1989)]. In IoxIIA, the change o...
266 (300) Author summary: 193 (200)
Chronic hypertension is associated with adverse risks for the mother and fetus in pregnancy. Metabolomic profiling can help elucidate disease pathways. Free fatty acid (FFA) levels are elevated hypertensive non-pregnant adults, FFAs appear to impair microvascular function contribute microangiopathy. The objective of this study compare metabolomic biomarkers chronic a pregnant cohort. We prospec...
s -----------------------------------------------------------------------------------------------------------------51 Poster Session ---------------------------------------------------------------------------------------------------------254 Index of Participants --------------------------------------------------------------------------------------------------266
Human epidermal growth factor receptor-2 (HER-2)/neu (ErbB2), a member of the epidermal growth factor family of receptors, is overexpressed in 20-30% of breast cancers. It is an attractive target for receptor-directed antitumor therapy using mAbs. Unlike other epidermal growth factor receptor family members, HER-2/neu does not bind a high-affinity ligand, but rather functions as the preferred d...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید